TRADR 2X LONG SNPS DAILY ETF (SNPX) Stock Price & Overview
NYSEARCA:SNPX • US46092D3439
Current stock price
The current stock price of SNPX is 20.7 USD. Today SNPX is down by -10.54%. In the past month the price decreased by -19.42%. In the past year, price increased by 762.5%.
SNPX Key Statistics
- Market Cap
- 28.773M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -9.81
- Dividend Yield
- N/A
SNPX Stock Performance
SNPX Stock Chart
SNPX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to SNPX. When comparing the yearly performance of all stocks, SNPX is one of the better performing stocks in the market, outperforming 99.59% of all stocks.
SNPX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.11 | 373.296B | ||
| AMGN | AMGEN INC | 15.28 | 190.378B | ||
| GILD | GILEAD SCIENCES INC | 15.19 | 169.926B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 115.264B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.78 | 80.002B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.53 | 43.521B | ||
| INSM | INSMED INC | N/A | 31.815B | ||
| BIIB | BIOGEN INC | 11.43 | 28.04B | ||
| NTRA | NATERA INC | N/A | 27.8B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 23.341B | ||
| MRNA | MODERNA INC | N/A | 21.157B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.471B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find more ETFs on the USA exchanges | Find stocks with similar TA and Setup ratings on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges
TRADR 2X LONG SNPS DAILY ETF / SNPX FAQ
What does TRADR 2X LONG SNPS DAILY ETF do?
Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer’s disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson’s Disease, Traumatic Brain Injury, and Stroke. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2020-12-07. The firm is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The firm is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
What is the stock price of TRADR 2X LONG SNPS DAILY ETF today?
The current stock price of SNPX is 20.7 USD. The price decreased by -10.54% in the last trading session.
What is the ChartMill technical and fundamental rating of SNPX stock?
SNPX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.